HC Wainwright Reaffirms Buy Rating for Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $6.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 430.97% from the stock’s current price.

Dyadic International Trading Down 0.9 %

Shares of DYAI stock opened at $1.13 on Thursday. Dyadic International has a twelve month low of $0.93 and a twelve month high of $2.67. The stock has a market cap of $33.44 million, a price-to-earnings ratio of -4.91 and a beta of 0.72. The company’s 50-day moving average price is $1.12 and its 200-day moving average price is $1.42. The company has a current ratio of 5.15, a quick ratio of 5.39 and a debt-to-equity ratio of 1.54.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.06. The company had revenue of $1.96 million for the quarter, compared to analyst estimates of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same period in the previous year, the business posted ($0.06) EPS. As a group, equities analysts predict that Dyadic International will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Dyadic International

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. boosted its stake in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 868,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the period. Chapin Davis Inc. owned approximately 2.97% of Dyadic International worth $903,000 at the end of the most recent quarter. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.